

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

oplicant:

Ken Shortman et al.

Examiner:

Unassigned

Serial No.:

10/584,180

Art Unit:

Unassigned

Filed:

June 23, 2006

Docket:

19975

For:

THERAPEUTIC AGENTS AND USES THEREFOR

Confirmation No. 4755

Dated:

August 22, 2006

Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R §§1.97 and 1.98, it is requested that the following reference, which is also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. International Publication No. WO 2005/060992 A1, dated July 7, 2005.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on August 22, 2006.

Dated: August 22, 2006

Yongzhi Yang

Applicants are submitting a copy of the above-cited reference.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,

Yongzhi Yang

Registration No. 56,310

Scully, Scott, Murphy & Presser, P.C. 400 Garden City Plaza - Suite 300 Garden City, New York 11530 (516) 742-4343

MY:vh

OINFORMATION DISCLOSURE CITATION (See several sheets if necessary)			Docket Number (Optional) 19975		Application Number 10/584,180		
			Applicant(s) Ken Shortman et al.				
(AUG 2 5 2006 g			Filing Date June 23, 2006	Group Art Unit			
THE THE WARTER OF	DOCUMENTS			<u> </u>			
*EXAMINER REF DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS		DATE
INITIAL DOCUMENT NOT DELL'			<u> </u>			IF APPRO	OPRIATE
							
	1						
	1						
	U.S. PATENT	L Γ APPLICA	TION PUBLICATIONS				<u>.</u>
XAMINER INITIAL REF DOCUMENT NUMBER DATE			NAME C		SUBCLASS FILING DATE IF APPROPRIATE		
						IF APPRO	<u> JPRIATE</u>
	FORE	IGN PATE	NT DOCUMENTS				
REF DOCUMENT NUMBER DATE			COUNTRY CLASS		SUBCLASS	SUBCLASS Translation YES NO	
WO 2005/060992 A1	July 7, 2005	PCT				1123	119
							-
	OTHER E	OCUMEN	TS (Including Author,	Title, Date, I	Pertinent Pages, Et	c.)	
•							
							<u> </u>
EXAMINER			DATE CONSIDERED				
EXAMINER: Initial if citation considered, whether not considered. Include copy of this form with next	or not citation is in	conforman	ice with MPEP Section 609; D	raw line thro	ough citation if not	in conform	nance and

Form PTO-A820 (also form PTO-1449)

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT Docket No. (Under 37 CFR 1.97(b) or 1.97(c)) 19975 In Re Application Of: Ken Shortman et al. Application No. Customer No. Group Art Unit Confirmation No. Filing Date Examiner 4755 10/584,180 June 23, 2006 Unassigned 23389 Unassigned Title: ZAMBRAZEUTIC AGENTS AND USES THEREFOR AUG 2 5 2006 Address to: **Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450 37 CFR 1.97(b) 1. Mark The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. 37 CFR 1.97(c) 2.

The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: ☐ the statement specified in 37 CFR 1.97(e); OR the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT Docket No. (Under 37 CFR 1.97(b) or 1.97(c)) 19975 Ken Shortman et al. In Re Application of: Customer No. **Group Art Unit** Confirmation No. Application No. Filing Date Examiner June 23, 2006 23389 4755 10/584,180 Unassigned Unassigned THERAPEUTIC AGENTS AND USES THEREFOR Title: AUG 2 5 2006 Payment of Fee (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p)) A check in the amount of is attached. ☑ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below. Charge the amount of \boxtimes Credit any overpayment. Charge any additional fee required. ☐ Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. Certificate of Mailing by First Class Mail Certificate of Transmission by Facsimile* I hereby certify that this correspondence is being deposited I certify that this document and authorization to charge deposit with the United States Postal Service with sufficient postage account is being facsimile transmitted to the United States as first class mail in an envelope addressed to Patent and Trademark Office (Fa "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on August 22, 2006 (Date) Signature of Person Mailing Correspondence Signature Yongzhi Yang Typed or Printed Name of Person Mailing Certificate Typed or Printed Name of Person Signing Certificate *This certificate may only be used if paying by deposit account. Dated: August 22, 2006 Signatur Yongzhi Yang Registration No.: 56,310 SCULLY, SCOTT, MURPHY & PRESSER, P.C. 400 Garden City Plaza, Suite 300 Garden City, NY 11530

cc: